Peripheral neuropathy is a known side effect of several chemotherapy agents, including vinca alkaloids and platinum-based chemotherapy. Early recognition and monitoring of this side effect is an important role of the pediatric oncology nurse. There are a variety of peripheral neuropathy assessment tools currently in use, but the usefulness of these tools in identifying and grading neuropathy in children varies, and there is currently no standardized tool in place to evaluate peripheral neuropathy in pediatric oncology. A systematic review was performed to identify the peripheral neuropathy assessment tools that best evaluate the early onset and progression of peripheral neuropathy in pediatric patients receiving vincristine. Because of the limited information available in pediatric oncology, this review was extended to any pediatric patient with neuropathy. A total of 8 studies were included in the evidence synthesis. Based on available evidence, the pediatric-modified Total Neuropathy Scale (ped-m TNS) and the Total Neuropathy Score-pediatric version (TNS-PV) are recommended for the assessment of vincristine-induced peripheral neuropathy in children 6 years of age and older. In addition, several studies demonstrated that subjective symptoms alone are not adequate to assess for vincristine-induced peripheral neuropathy. Nursing assessment of peripheral neuropathy should be an integral and regular part of patient care throughout the course of chemotherapy treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988942 | PMC |
| http://dx.doi.org/10.1177/1043454218762705 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Various topical drug combination assessed using a neurosensory stent for chronic intraoral neuropathic pain: a pilot study.
J Oral Facial Pain Headache
September 2024
Department of Pediatric Dentistry, Barzilai Medical Center, 7830604 Ashkelon, Israel.
Chronic intraoral neuropathic pain (NP), often developing post-dental procedures, poses significant management challenges. The prevalent use of systemic treatments, with their frequent substantial side effects, emphasizes the need for alternative therapeutic strategies. Our aim is to explore the efficacy and adherence with a topical drug regimen delivered through a neurosensory stent (NS) for treating chronic neuropathic pain (NP) within the oral cavity.
View Article and Find Full Text PDFObjective: To create a comprehensive overview of imaging methods for diagnosing pudendal neuralgia.
Methodology: Literature review.
Conclusion: Pudendal neuralgia is a chronic pain condition that is difficult to diagnose.
Comparing the clinical efficacy of preganglionic and preganglionic plus ganglionic transforaminal epidural steroid injections for lumbosacral radicular pain.
Neurosciences (Riyadh)
January 2025
From the Department of Algology (Göksu), Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, from the Department of Algology (Celik, Akcaboy, Şahin), University of Health Sciences Ankara City Hospital, Ankara, from Ankara Gaziler PMR Training and Research Hospital (Baran), University of Health Sciences, Ağrı, from the Department of Algology (Yıldız), University of Health Sciences Ankara Etlik City Hospital, Ankara, from the Department of Algology (Kaya), Adıyaman University Training and Research Hospital, Adıyaman, and from the Department of Algology (Ayhan), Dumlupinar University Kutahya Evliya Celebi Training and Research Hospital, Kütahya, Turkey.
Objectives: To compare the effectiveness of preganglionic transforaminal epidural steroid injection (TFESI) with preganglionic plus postganglionic TFESI.
Methods: Patients with unilateral radicular pain and disc pathology were randomly assigned to either the preganglionic group or the preganglionic plus postganglionic group. All patients were evaluated using a numeric rating scale (NRS) and a patient satisfaction scale (PSS) at the third week and the third month after treatment.
Gut microbiota in Alzheimer's disease: understanding molecular pathways and potential therapeutic perspectives.
Ageing Res Rev
January 2025
i+HeALTH Strategic Research Group, Department of Health Sciences, Miguel de Cervantes European University (UEMC), 47012 Valladolid, Spain; Physical Activity and Health Research Group (PaHerg), Research Institute of the Hospital 12 de Octubre ('imas12'), 28041 Madrid, Spain. Electronic address:
Accumulating evidence suggests that gut microbiota (GM) plays a crucial role in Alzheimer's disease (AD) pathogenesis and progression. This narrative review explores the complex interplay between GM, the immune system, and the central nervous system in AD. We discuss mechanisms through which GM dysbiosis can compromise intestinal barrier integrity, enabling pro-inflammatory molecules and metabolites to enter systemic circulation and the brain, potentially contributing to AD hallmarks.
View Article and Find Full Text PDFDemyelinating neuropathy as the initial presentation of familial E200K Creutzfeldt-Jakob disease in two patients.
Ann Clin Transl Neurol
January 2025
Institut du Cerveau et de la Moelle Épinière, ICM, Sorbonne Université, INSERM, CNRS, Paris, France.
Objective: To describe peripheral neuropathy associated with familial Creutzfeldt-Jakob disease.
Methods: We report two unrelated patients with genetic Creutzfeldt-Jakob disease with demyelinating peripheral neuropathy as initial presentation, with a comprehensive clinical, electrophysiological and neuropathological description.
Results: Both patients exhibited gait disturbance and paresthesia.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!